A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
Running, not enrolling · Phase 3 · Has a placebo group
Conditions studied: Plaque Psoriasis
In brief
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
Key facts
- Study ID
- NCT06095102
- Run by
- Janssen Research & Development, LLC
- People needed
- 311
- Starts
- 2023-10-12
- Expected to finish
- 2027-02-17
- Last updated by the study team
- 2026-07-06
Who can join
Age: 12 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
- Candidate for phototherapy or systemic treatment for plaque psoriasis
- Need to meet criteria: Total body surface area (BSA) greater than or equal to (>=)1 percent (%) at screening and baseline, and investigator global assessment (IGA) (overall) >=2 at screening and baseline and at least one of the following: scalp-specific investigator global assessment (ss-IGA) score >=3 at screening and baseline, and/or static physician's global assessment of genitalia (sPGA-G) >=3 at screening and baseline, and/or physician's global assessment of hands and feet (hf-PGA) score >=3 at screening and baseline
- Failed to respond to at least 1 topical therapy (example, corticosteroids, calcineurin inhibitors, and/or vitamin D analogs) used for treatment of psoriasis
- Confirmation of plaque psoriasis in a non-special area (example, areas excluding scalp, genital, palmoplantar) at screening and baseline
You may not qualify if…
- Nonplaque form of psoriasis (example, erythrodermic, guttate, or pustular)
- Dermatoses other than plaque psoriasis (such as contact dermatitis) or palmoplantar pustulosis of the palmoplantar area (if hf-PGA >=3 at baseline)
- Current drug-induced psoriasis (example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
- A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to JNJ-77242113 or its excipients
Where it is running
- Derma-B Kft — Debrecen, Hungary
- Center for Dermatology and Plastic Surgery — Scottsdale, Arizona, United States
- Johnson Dermatology — Fort Smith, Arkansas, United States
- California Dermatology & Clinical Research Institute — Encinitas, California, United States
- Forcare Clinical Research Inc — Tampa, Florida, United States
- Hamilton Research LLC — Alpharetta, Georgia, United States
- Arlington Dermatology — Rolling Meadows, Illinois, United States
- Dundee Dermatology — West Dundee, Illinois, United States
- Dawes Fretzin Clinical Research Group LLC — Indianapolis, Indiana, United States
- Indiana Clinical Trial Center — Plainfield, Indiana, United States
- Dermatology and Advanced Aesthetics — Lake Charles, Louisiana, United States
- Allcutis Research 1 — Beverly, Massachusetts, United States
- Hamzavi Dermatology — Fort Gratiot, Michigan, United States
- Minnesota Clinical Study Center — New Brighton, Minnesota, United States
- MediSearch Clinical Trials — Saint Joseph, Missouri, United States
- Skin Specialists — Omaha, Nebraska, United States
- Schweiger Dermatology Group — East Windsor, New Jersey, United States
- Optima Research — Boardman, Ohio, United States
- Oregon Dermatology and Research Center — Portland, Oregon, United States
- Paddington Testing Co, Inc. — Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
- Arlington Research Center, Inc. — Arlington, Texas, United States
- Center for Clinical Studies 1 — Houston, Texas, United States
- Austin Institute for Clinical Research — Pflugerville, Texas, United States
- Pecsi Tudomanyegyetem — Borgyogyaszati Klinika, Hungary
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.